Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease (NIC-PD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01560754 |
|
Recruitment Status : Unknown
Verified September 2015 by James BOYD MD, University of Vermont.
Recruitment status was: Active, not recruiting
First Posted : March 22, 2012
Last Update Posted : September 29, 2015
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson's Disease | Drug: nicotine transdermal patch | Phase 2 |
In order to prove the disease-modifying potential of transdermal nicotine treatment, an explanatory design with a 2 months wash-out phase before endpoint assessment will be performed. The primary objective is to demonstrate superiority measured by the difference between the nicotine arm and the placebo arm in the change in total UPDRS score (part I-III) between baseline and end of month 14 (12 months treatment and 2 months wash-out, see 3.1). The total UPDRS score will be determined by an independent rater, who is not involved in any other study-related procedure (e.g. reporting of adverse events). Change in total UPDRS score is the most widely applied measure in similar clinical trials assessing long-term beneficial effects of drugs. The investigators will also determine whether the slope of the curves for the total UPDRS score in active- and placebo-treated subjects show a tendency to converge over time. For this purpose the UPDRS will be determined three times after placebo/nicotine withdrawal at the end of the study during Visit 7,8, and 9 (i.e. four times including Visit 6).
Approximately 250 subjects will be screened at 25-30 centers in Germany and the USA. The recruitment period will be 18 months. In the screening phase, subjects will be evaluated for eligibility for enrolment into the treatment phase. The investigators expect that screening of 250 subjects will result in 160 eligible subjects who will be randomly assigned 1:1 to treatment with either transdermal nicotine or transdermal placebo patch.
The treatment phase consists of a titration period (16 weeks, to find the highest dosage tolerated by the subject with a target of 28 mg) and a maintenance period (week 17 to week 52 with the highest tolerated dosage of nicotine).
The treatment phase will be followed by an 8 week wash-out phase (3 weeks down titration and 5 weeks run out).
Dose adjustments are permitted for adverse events and have to be documented thoroughly.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 160 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA |
| Study Start Date : | October 2012 |
| Estimated Primary Completion Date : | August 2016 |
| Estimated Study Completion Date : | December 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Transdermal nicotine patch
Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
|
Drug: nicotine transdermal patch
Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
Other Names:
|
|
Placebo Comparator: Transdermal placebo patch
Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
|
Drug: nicotine transdermal patch
Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
Other Names:
|
- The primary endpoint is calculated as the difference between the nicotine arm and the placebo arm in the change in total UPDRS I-III score between baseline and 60 weeks (14 months) (52 weeks treatment plus 8 weeks wash-out). [ Time Frame: From Baseline to week 60 ]The primary objective is to demonstrate superiority measured by the difference between the nicotine arm and the placebo arm in the change in total UPDRS score (part I-III) between baseline and end of month 14 (12 months treatment and 2 months wash-out
- The change in total UPDRS I-III score between baseline and 52 weeks (12 months) [ Time Frame: Baseline to 52 weeks ]
- Parkinson's Disease Questionaire - 8(PDQ-8) that is calculated as the change between baseline and 60 weeks [ Time Frame: Baseline and week 60 ]
- The frequency of adverse events will be analyzed [ Time Frame: Baseline through week 60 ]
- The 'time to initiation of a symptomatic treatment' is calculated from the date of randomization to the date that a subject initiates symptomatic therapy [ Time Frame: Baseline to initiation of symptomatic therapy, this timeframe will vary from subject to subject based on duration of disease and how well their PD is currently being managed ]
- Determine whether the slope of the curves for the total UPDRS score in active- and placebo-treated subjects show a tendency to converge over time [ Time Frame: Baseline to week 52 and week 60 ]
- Parkinson's Disease Questionnaire - 8 (PDQ-8), a patient completed questionaire, calculated as the change between baseline and week 52 [ Time Frame: Baseline and week 52 ]
- Scales for Outcomes of Parkinson's disease - Cognition (SCOPA-COG), is calculated as the change between baseline and week 52 [ Time Frame: Baseline and week 52 ]
- Beck Depression Inventory - II (BDI-II) that is calculated as the change between baseline and week 52 [ Time Frame: Baseline and week 52 ]
- Parkinson's Disease Sleep Scale (PDSS) that is calculated as the change between baseline and week 52 [ Time Frame: baseline and week 52 ]
- SCOPA-COG that is calculated as the change between baseline and 60 weeks [ Time Frame: Baseline and week 60 ]
- BDI-II that is calculated as the change between baseline and 60 weeks [ Time Frame: Baseline and Week 60 ]
- PDSS that is calculated as the change between baseline and week 60 [ Time Frame: Baseline and Week 60 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent
- Capability and willingness to comply with the study related procedures
- Age >/= 30 y
- Usage of effective contraception (see below) in fertile pre-menopausal female participants (from inclusion until end of wash out) Acceptable forms of effective contraception include established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception (condom or occlusive cap /diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository or male / female sterilization / or true abstinence.
- Diagnosis of PD according to the UK Brain Bank Diagnostic Criteria
- Early PD subjects within 18 months of diagnosis
- Hoehn and Yahr stage ≤ 2
- Patients not receiving or needing dopamine agonist or levodopa therapy presently or for the next year
- Stable treatment (>2 months) with MAO-B inhibitor (selegiline up to 10 mg/d or rasagiline up to 1 mg/d) allowable
Exclusion Criteria:
-
Clinical signs indicating a Parkinson syndrome other than idiopathic PD e.g.:
- Supranuclear gaze palsy
- Signs of frontal dementia
- History of repeated strokes with stepwise progression of Parkinsonian features
- History of repeated head injury or history of definite encephalitis
- Cerebellar signs
- Early severe autonomic involvement
- Babinski's sign
- History of exposure to or current treatment with neuroleptic drugs or anticraving substances
- History of nicotine use within five years of the baseline visit
- Previous history of allergic response to nicotine application or any of the patch excipients (see protocol sec. 10.2)
- Previous history of allergic response to transdermal patches
- Pre-existing dermatological disorder that could disturb transdermal patch application in the opinion of the investigator (e.g. generalized / systemic or local neurodermatitis, psoriasis, chronic dermatitis, urticaria, etc.)
- Previous treatment with antiparkinsonian drugs (e.g. levodopa, dopamine agonists, etc.) other than MAO-B inhibitors
-
History of unstable or serious cardiovascular diseases
- Unstable or worsening angina pectoris,
- History of recent myocardial infarction or cardiac failure (NYHA from II to IV), myocardial insufficiency
- History at inclusion of serious cardiac arrhythmia,
- History of recent stroke or occlusive peripheral vascular disease, vasospasm
- History of structural brain disease, cerebrovascular diseases
- History of severe uncontrolled arterial hypertension
- History of severe pulmonary disease (asthma, COPD)
- History of auto-immune disease
- History of Hyperthyroidism
- History of Pheochromocytoma
- History of seizures / epilepsy
- History of amyosthenia / myasthenia gravis, pseudo-myasthenic syndrome
- Dementia defined as Mini Mental State Examination (MMSE) score ≤ 24
- Moderate depression (BDI-II score >24)
- Suicide or suicide ideation
- History or presence of specific psychiatric disorders, acute psychosis, hallucinations, pathologic gambling, alcohol or substance abuse
- Patients under treatment with dihydropyridines (e.g. nifedipine, nicardipine, amlodipine)
- History of uncontrolled diabetes
- History of recent gastroduodenal ulcer (< 3 months) or presence of severe (acute and chronic) gastritis
- History of known hepatobiliary or renal insufficiency
- Pregnancy or lactation period
- Simultaneous participation or previous participation within 60 days before screening in another clinical drug or medical device study. Other Trials that do not affect the NIC-PD Study (NIT, health economics evaluations, questionnaires, genetic studies) could be allowed, but have to be approved and documented by the steering committee
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01560754
Show 24 study locations
| Principal Investigator: | Wolfgang Oertel, MD | Philipps-University Marburg, Germany / Global and German Principal Investigator | |
| Principal Investigator: | James Boyd, MD | University of Vermont / United States Principal Investigator |
| Responsible Party: | James BOYD MD, United States Principal Investigator, University of Vermont |
| ClinicalTrials.gov Identifier: | NCT01560754 |
| Other Study ID Numbers: |
KKS-135 |
| First Posted: | March 22, 2012 Key Record Dates |
| Last Update Posted: | September 29, 2015 |
| Last Verified: | September 2015 |
|
Randomized Placebo-controlled Double-blind |
Multi-center Disease-modifying potential transdermal nicotine |
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases Nicotine |
Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |